Page last updated: 2024-12-11

crotarbital

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

crotarbital: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5364821
SCHEMBL ID712976
SCHEMBL ID2285746
MeSH IDM0040687

Synonyms (48)

Synonym
ethyl(crotyl)barbiturate
nsc125735
ethyl-crotyl-barbiturate
kalipnon
nsc-125735
mepertan
barbituric acid, 5-(2-butenyl)-5-ethyl-
crotarbital
barotal
go 1046
2,6(1h,3h,5h)-pyrimidinetrione, 5-(2-butenyl)-5-ethyl-
calypnone
barotalum
kalypnetten
1952-67-6
5-(2-butenyl)-5-ethylbarbituric acid
5-ethyl-5-crotylbarbituric acid
kalypnon
crotylbarbital
crotylbarbitalum
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-butenyl)-5-ethyl-
einecs 217-777-9
nsc 125735
ethyl (crotyl)barbiturate
5-(2-butenyl)-5-ethyl-1h,3h,5h-pyrimidine-2,4,6-trione
5-aethyl-5-crotylbarbitursaure [german]
5-[(e)-but-2-enyl]-5-ethyl-1,3-diazinane-2,4,6-trione
5-aethyl-5-crotylbarbitursaure
unii-sxw2hl5ju7
sxw2hl5ju7 ,
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-butenyl)-5-ethyl-, (e)-
crotarbital [who-dd]
crotylbarbitone
28360-89-6
5-crotyl-5-ethylbarbituric acid
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-buten-1-yl)-5-ethyl-
crotarbitone
go-1046
crotylbital
SCHEMBL712976
KNMOHCLEINXVBG-HWKANZROSA-N
5-[2-butenyl]-5-ethyl-2,4,6(1h,3h,5h)-pyrimidinetrione #
SCHEMBL2285746
HY-101629
CS-6573
(e)-crotylbarbital
Q5189013
AKOS040732215
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (87.50)18.7374
1990's1 (12.50)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (10.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]